RIFADIN IV Rx
Generic Name and Formulations:
Rifampin 600mg/vial; lyophilized pwd for IV infusion after reconstitution.
Indications for RIFADIN IV:
Initial treatment and retreatment of susceptible tuberculosis, when oral therapy is not feasible.
10mg/kg once daily; max 600mg/day. Caps: give 1hr before or 2hrs after meals with water. IV: infuse over 30mins (100mL) or within 3hrs (500mL). Initial phase: treat for up to 2 months with isoniazid and pyrazinamide (streptomycin or ethambutol may be added as fourth drug if resistance to isoniazid exists). After initial phase, continue rifampin with isoniazid for at least 4 months; longer if sputum or culture remains (+), with resistant organisms, or HIV (+).
10–20mg/kg once daily; max 600mg/day. Caps: give 1hr before or 2hrs after meals with water. IV: infuse over 30mins (100mL) or within 3hrs (500mL). Initial phase: treat for up to 2 months with isoniazid and pyrazinamide (streptomycin or ethambutol may be added as fourth drug if resistance to isoniazid exists). After initial phase, continue rifampin with isoniazid for at least 4 months; longer if sputum or culture remains (+), with resistant organisms, or HIV (+). Preparation of suspension: see full labeling.
Concomitant ritonavir-boosted saquinavir (increased risk of severe hepatotoxicity). Concomitant atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir. Rifamycin hypersensitivity.
Not recommended for intermittent therapy (risk of renal hypersensitivity reactions; rare). Monitor for hypersensitivity reactions (eg, DRESS); discontinue if occur. Hepatic impairment; monitor LFTs at baseline, then every 2–4 weeks. Discontinue if signs of hepatocellular damage occurs. Diabetes. May stain teeth, body secretions, contact lenses. IV: avoid extravasation. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. Antagonizes anticonvulsants, digitoxin, antiarrhythmics, oral anticoagulants (monitor prothrombin time), azole antifungals, barbiturates, β-blockers, CCBs, chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac glycosides, clofibrate, oral or other hormonal contraceptives (consider nonhormonal methods), dapsone, diazepam, doxycycline, fluoroquinolones, haloperidol, sulfonylureas, levothyroxine, methadone, narcotic analgesics, progestins, quinine, tacrolimus, theophylline, tricyclic antidepressants, zidovudine, atovaquone, enalapril, sulfasalazine; may need to adjust dose. May be potentiated by atovaquone, probenecid, cotrimoxazole. May be antagonized by ketoconazole. Separate dosing of antacids by at least 1hr. Avoid concomitant halothane. May cause false (+) urine tests for opiates. May inhibit assays for serum folate and Vit. B12 (consider alternative methods). Perform LFTs and use contrast media prior to morning dose.
GI disturbances, jaundice, headache, fever, drowsiness, fatigue, ataxia, dizziness, inability to concentrate, mental confusion, muscular weakness, pain in extremities, generalized numbness, visual disturbances, elevated BUN and serum uric acid, menstrual disturbances, urticaria, rash, edema; rare: hepatitis, abnormal LFTs, blood dyscrasias, hypersensitivity reactions.
Caps 150mg—30; 300mg—60, 100; Vials—1
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Improving Performance of Everyday Activities Is Critical in Schizophrenia
- Analysis Finds Lithium Maintenance Most Effective as Monotherapy in Bipolar Disorder
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Web-Based Intervention Targets Parental Behaviors That May Affect Adolescent Anxiety, Depression
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders
- Mortality Rates for Substance Use Disorders, Intentional Injuries Vary Widely By Country
- Facial Emotion Recognition Differentiates Behavioral Variant Frontotemporal Dementia From MDD
- The Challenge of Helping Uninsured Patients While Protecting Practice Finances
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed